63results about How to "Repress transcription" patented technology

The present invention discloses a coronary artery medicine coating scaffold for inhibiting endometrial hyperplasia and preventing restenosis in the scaffold. It includes dilating scaffold base body and inner coating layer coated on the dilating scaffold base body, the above-mentioned inner coating layer is formed from medicine carrier and ligustrazine, their mass ratio is 3:1-1:3, the above-mentioned inner coating layer is one of methyl acrylate, methyl methacrylate copolymer, polylactic acid, polyglycollic acid, polymonoracemic lactic acid, polylactide-diglycolide polymer, phosphorylcholine, ethyl polyurethane inorganic micropore aluminium oxide and cellulose or their composite.

The invention relates to a pTerm-SC plasmid as well as a construction method and application thereof. The pTerm-SC plasmid comprises a repE gene, a sopA gene, a sopB gene, a sopC gene, an ori2 replicon, an oriV replicon, prokaryote transcription terminators and antibiotics resistance genes. The pTerm-SC plasmid has the characteristics of very low copy number, high volume and stability and the like, can be applied to gene engineering fields such as the cloning, the screening, sequencing and the genome construction of complex-structure genes including repetitive-sequence genes, instable genes and long-fragment genes and has important role in the high-efficiency and high-quality synthesis of genes.

The invention discloses an application of improved ATMT (Agrobacterium Tumefaciens-Mediated Transformation) to construction of trichoderma atroviride T23 deltaCrel. The application is characterized in that the genomic DNA of trichoderma atroviride T23 is taken as a template, PCR (Polymerase Chain Reaction) amplification is carried out on the Crel gene sequence, and thus upstream and downstream flanking sequences of the Crel gene are obtained; then leading in respectively to knock out upstream and downstream of plasmid pC1300qh, so as to form recombinant plasmid pC1300qh-deltaCrel; converting escherichia coli competence of the recombinant plasmid pC1300qh-deltaCrel, performing verification, screening positive clone, extracting recombinant plasmid pC1300qh-deltaCrel, leading in agrobacterium tumefaciens AGL1, and carrying out improved ATMT. By using the improved ATMT technique, a trichoderma atroviride carbon metabolism inhibiting factor CRE1-knocked-out mutant strain is successfully constructed; the T23 deltaCrel bacterial strain has the functions of promoting secretion and activity of degrading enzyme of cell walls of trichoderma spp., and indirectly improving the function of trichoderma spp. to antagonize pathogenic bacteria.

The invention discloses application of a RBP1 gene in sow ovarian granular cells. RBP1 is taken as a research object, and a molecular and cell biological method is adopted to study the application ofthe RBP1 in sow ovarian granular cells. The molecular and cell biological method includes the following steps that through ChIP-Seq, it is found that the enrichment degree of H3K4me3 is different in RBP1 gene promoter regions in follicles different in size; through qRT-PCR, it is found that the expression quantity of the RBP1 gene in follicles different in size is different significantly. By promoting or inhibiting the enrichment degree of H3K4me3 in the sow ovarian granular cells, it is found that promotion of the enrichment degree of H3K4me3 can promote transcription of the RBP1 gene, and inhibition of the enrichment degree of H3K4me3 can inhibit transcription of the RBP1 gene; through RBP1 over-expression or interference with RBP1, it is found that RBP1 can promote proliferation of thesow ovarian granular cells and inhibit apoptosis.

The invention relates to the field of biotechnology, and in particular relates to an application of a VGLL4 gene in treatment of tumors and a related medicament of the VGLL4 gene. The invention discloses a separated VGLL4 gene and a homologous sequence thereof, a VGLL4 protein and an application of related protein of the VGLL4 protein in preparation or screening of tumor treatment medicaments. Researches discover that VGLL4 can inhibit the transcription of a TEAD4 target gene CDX2 highly expressed in stomach cancer by inhibiting YAP-mediated TEAD4 transcriptional activation, thereby achieving the aim of inhibiting proliferation of cancer cells at last. The VGLL4 gene provided by the invention can be used for preparing medicaments for inhibiting the growth of tumor cells, developing anti-cancer medicaments and preparing medicaments for early diagnosis of cancer and medicaments for operation prognosis, so that the VGLL4 gene provides a new technical means for treating cancers, and has a great market value.

The invention discloses a preparation method of a double-response nano prodrug for cancer synergistic treatment. The preparation method comprises the following steps: with cis-platinum as a precursor,performing carboxylation modification and then carboxyl activation on the cis-platinum; mixing the activated carboxyl cis-platinum with L-arginine; and forming a double-response nano prodrug with thecis-platinum/arginine composite structure through dehydration condensation of intermolecular carboxyl and amino. The method has advantages of being simple, green, and mild and being low in cost. Thecis-platinum can effectively inhibit DNA transcription to realize the effect of treating cancer; cis-platinum can promote H2O2 generation under the induction of NOX enzyme in vivo and the arginine serving as human amino acid can react with H2O2 to generate NO, so that tumor extinction is further induced. Therefore, the nano prodrug is expected to be developed into an efficient anticancer drug.

The present invention provides a polycyclic compound represented by formula (I) and a use in dual inhibitors of AR and BET. Specifically, the present invention provides the use of a compound represented by formula (I) or optical isomers, solvates, pharmaceutically acceptable salts, prodrugs, tautomers, mesomers, racemates, enantiomers, diastereomers, mixture form, metabolites, metabolic precursorsor isotopic substitution form thereof in the preparation of dual inhibitors of AR and BET. Experimental results show that the compounds of the present invention can not only inhibit the transcriptionof PSA and FKBP5 downstream of AR, but also inhibit the transcriptional activity of AR-F876L mutants resistant to anthralin, and also downregulate the expression of BRD4 downstream protein c-Myc, andthe compounds have good binding affinity to AR and BET proteins. The experiment suggests that the compound of the present invention can inhibit the activity of AR and BET protein at the same time, and has a good application prospect in the preparation of medicine for preventing and/or treating diseases related to BET protein.

The invention relates to the technical field of biology, in particular to application of lycopene in preparation of antiviral drugs. The lycopene has a new function of inhibiting cysteine protease activity, has a broad-spectrum inhibition effect on viruses containing 3CLpro, and can be used for research and development of antiviral drugs.

The invention discloses antibacterial, worm-expelling and fresh-preserving cotton cloth which is prepared by the steps of: dipping the pure cotton cloth in pepper water with concentration of 1% for at least 10min, and then spraying molecular chitin or chitosan with the amount of 2.5g/sq.m on the cotton cloth after the cotton cloth is dried. The cotton cloth treated by the method is made into various packaging supplies with a sterilizing rate of 60%, a worm-expelling rate of 98% and a valid period of up to half a year. The packaging bag made of the antibacterial, worm-expelling and fresh-preserving pure cotton cloth is safe and non-toxic for packaging cereal products and dried fruits, good for people's health, simple and convenient to make, and worth popularizing.

The invention discloses a novel pesticide for controlling plant bacterial diseases. The novel pesticide is prepared from raw materials in percentage by weight as follows: 1%-10% of berberine sulfate, 1%-10% of a solubilizer, 5%-15% of pesticide adjuvants and 0.1%-1% of a preservative, wherein berberine sulfate is chemically synthesized or extracted and purified from a traditional Chinese medicine, and the molecular formula is C20H18NO8S; the mole ratio of the solubilizer to berberine sulfate is 1:1-2; the novel pesticide for controlling plant bacterial diseases mainly contains 0.5%-1% of berberine sulfate and the balance of the solubilizer, the pesticide adjuvants and water; the novel pesticide adopts a form of a microemulsion, an aqueous solution or an emulsion in water. The application method of the novel pesticide comprises the following steps: the pesticide is diluted to 500-1,000 times solution, and the solution is used for root irrigation or sprayed to rhizome bases of tobacco plants after tobacco seedlings are transplanted for about 7-10 days, is applied once every 8-11 days and is continuously applied 3-4 times. The novel pesticide has wide antibacterial spectrum, does not produce drug resistance easily, is low-toxic for human and livestock, is residue-free and produces little pollution, and the control effect on the plant bacterial diseases such as tobacco bacterial wilt and the like is better than that of agricultural streptomycin.

The invention provides an organic selenium composition which comprises selenium-enriched edible fungus powder, wolfberries, honeysuckle and vitamin E. The organic selenium composition can be used as a food, can also be used as a medicine, can be taken for a long period of time, and is capable of improving the human immunity, preventing tumors, inhibiting growth of cancer cells and synthesis of DNA, RNA and protein, inhibiting oncogene transcription and interfering with metabolism of carcinogenic substances. The selenium-enriched edible fungus powder is matched with the wolfberries, the honeysuckle, the vitamin E and Jerusalem artichoke for use, so that the synergistic effects can be developed, the human immunity is enhanced, especially, the immunity of patients receiving tumor chemotherapy is enhanced, and the chemotherapy effect is strengthened.

The invention discloses a TALER protein for displaying transcription inhibiting action through steric hindrance and application thereof. The invention protects application of the TALER protein in inactivating a target promoter. The upper stream and lower stream of the target promoter are respectively provided with at least one target spot of the TALER protein; or the upper stream of the target promoter is not provided with the target spot of the TALER protein, but the lower stream is provided with at least one target spot of the TALER protein. The invention also protects application of the TALER protein in inactivating the coding gene of the target protein. The expression of the coding gene of the target protein is started by the target promoter. The upper stream and lower stream of the target promoter are respectively provided with at least one target spot of the TALER protein; or the upper stream of the target promoter is not provided with the target spot of the TALER protein, but the lower stream is provided with at least one target spot of the TALER protein. The TALER protein has important value for regulation expression modes and function studies of proteins.

The invention belongs to the field of hepatitis B prevention and treatment, and in particular relates to a hepatocyte nuclear factor 4a specificity short hairpin RNA with an inhibition effect for hepatitis B virus replication and applications thereof. The technical problem to be solved by the invention is to provide a novel effective choice for HBV resistant treatment. The technical scheme of the technical problem solved by the invention is to provide a specificity short hairpin RNA aiming at the hepatocyte nuclear factor 4a and a carrier capable of expressing the sequence. The shRNA sequence and the expression carrier thereof provided by the invention are testified to be able to inhibit internal HBV transcription and copy effectively and have no obvious side effects, and provide a novel effective choice for HBV resistance, and have favorable application prospects in preparing HBV-resistant medicaments.

The invention discloses application of Mad1 protein in regulation and control of fungal sporulation and germination. Metarhizium anisopliae is used as a starting strain, a mad1 gene knockout strain (delta mad1) is obtained through a homologous recombination method, and the growth rate, sporulation and germination biological characteristics of a wild strain and the delta mad1 are measured. The wildstrain and delta mad1 spore suspensions are used for soaking the root of a peanut seedling to detect the transcription level of a linolenic acid metabolic pathway gene of the treated peanut root. Experimental results show that compared with the wild strain, the germination rate and sporulation quantity of the delta mad1 are remarkably reduced, the delta mad1 remarkably inhibits transcription of the linolenic acid metabolic pathway gene after acting on a plant, and thus the Mad1 can promote sporulation and germination of the Metarhizium anisopliae and up-regulate the transcription level of thelinolenic acid metabolic pathway gene. Theoretical support is provided for improvement and industrial production of fungal strains, and basic data are provided for Mad1 induced plant response to regulation and control of interaction between the Metarhizium anisopliae and the plant.

The invention discloses a method for inhibiting geminivirus infection by overexpression of arabidopsis ABI5 protein, which inhibits transcription of geminivirus coding genes by overexpression of plant transcription factor ABI5 protein and combination of ABI5 protein and a promoter of geminivirus through specificity, and realizes improvement of virus resistance of plants.

The invention discloses a shRNA molecule capable of inhibiting expression of the human AEBP1 gene. According to the human AEBP1 gene (with a serial number of NM_001129.4) in Genbank, four shRNA molecules are designed and are synthesized targeted at the sequence of shRNA; two synthesized complementary single-stranded shRNA molecules are subjected to annealing to form a double-stranded shRNA molecule; and the double-stranded shRNA molecule is linked to a lentivirus vector to construct four lentivirus interference RNA plasmids. The shRNA plasmids are used for transfection of a Huh7 cell line containing AEBP1, and relative quantitative analysis is carried out on the AEBP1 gene through real-time quantitative PCR so as to evaluate inhibition effect on the expression of the AEBP1 gene. Results of relative quantitative analysis show that AEBP1-shRNA1 can inhibit transcription of 82.3% of AEBP1 and AEBP1-shRNA2 can inhibit transcription of 75.7% of AEBP1.

The invention discloses application of sulforaphane and derivatives thereof as a bacterial effector protein transcription inhibitor. The invention provides an application of sulforaphane and derivatives thereof in any one of application of the following 1) and 7): 1) prevention and treatment of pathogenic bacteria; 2) improvement of the resistance of plants to pathogenic bacteria; 3) inhibiting ofpathogenicity of pathogenic bacteria; 4) inhibiting of the function of a pathogenic bacterium III type secretion system; 5) inhibiting of the expression of effector protein related genes of a pathogenic bacterium type III secretion system; 6) inhibiting of the expression of a pathogenic bacteria transcription factor hrpL; and 7) using as a pathogenic bacteria effector protein transcription inhibitor. Experiments prove that the sulforaphane and the derivatives thereof can inhibit the function of a pathogenic bacteria type III secretion system by specifically inhibiting transcription of the pathogenic bacteria type III secretion system, can resist invasion of pathogenic bacteria without destroying interaction between plants and beneficial microorganisms, and have a wide application prospectin prevention and treatment of plant pathogenic bacteria.

The invention provides application of xanthohumol in preparation of a SARS-CoV-2 inhibitor. The anti-virus active compound xanthohumol with high binding capacity with a Mpro protease is obtained through structure-based virtual screening by taking the Mpro protease, which causes lung inflammation, of the SARS-CoV-2 as a target point. The xanthohumol is bound with the target Mpro protease to inhibitthe activity of the Mpro protease, so that replication and transcription of viruses are inhibited, and the effect of resisting SARS-CoV-2 infection is achieved. The xanthohumol can be applied to preparation of the SARS-CoV-2 Mpro protease inhibitor so as to be applied to preparation of a medicine for preventing and/or treating SARS-CoV-2 inflammation. The binding energy of the xanthohumol and theMpro protease is -63.427 KJ/mol, the IC50 of the xanthohumol to the Mpro protease is 4.97 +/- 1.79 [mu]M, and the inhibition constant Ki value is 2.14 [mu]M.

The invention discloses a composition for treating testicular atrophy and a preparation method thereof, and relates to the field of medicines for treating testicular atrophy, in particular to a composition for treating testicular atrophy and a preparation method thereof. The invention aims to solve the problem of poor testicular atrophy treatment effect of the existing platelet-rich plasma. The composition comprises a platelet lysis buffer and a BMSCs exosome, and the volume ratio of the platelet lysis buffer to the BMSCs exosome is 1: 1. The platelet lysate sPL and the BMSCs exosome are prepared into the composition for promoting cell regeneration, and the composition is used for improving and treating testicular atrophy of rats. By taking activation and recovery of functions of spermatogonial stem cells as an entry point, a sPL preparation method capable of increasing secretion of three growth factors capable of promoting proliferation of spermatogonial stem cells, namely EGF, bFGF and IGF-1, and a BMSCs culture method for highly expressing miR-486-5p exosomes are found. The medicine is used for treating testicular atrophy.

The invention discloses an application of two phenylethanoid glycoside compounds, namely verbascoside and isoacteoside to preparation of antidiabetic drugs. Monomeric compounds of verbascoside and isoacteoside can be extracted from various plants, so that the source is wide, the toxicity is low, and the stability is good. An inventor proves by experiments that (1) the verbascoside and the isoacteoside can protect and repair an injury of an NIT-1 pancreatic beta-cell caused by alloxan, and promote insulin secretion of the injured pancreatic beta-cell in a dose-dependent manner; (2) a free radical injury of the pancreatic beta-cell caused by the alloxan can be reduced; and (3) the activity of the pancreatic cell can be enhanced, the survival rate of the cell is improved, and the mechanisms of the verbascoside and the isoacteoside can activate transcription of an apoptosis-inhibiting gene Bcl-2 mRNA and inhibit transcription of an apoptosis-promoting gene Bax mRNA and finally inhibit transcription of a Caspase-3 gene and expression of Caspase-3 and Bax proteins, thereby inhibiting apoptosis of the pancreatic cell injured by the alloxan. Therefore, the two phenylethanoid glycoside compounds, namely the verbascoside and the isoacteoside disclosed by the invention have potential value of being developed into antidiabetic candidate drugs.

The invention belongs to the technical field of ceramic tiles, and particularly relates to super wear-resistant antiviral glaze, a ceramic tile and a preparation method of the ceramic tile, and the glaze comprises the following raw materials in parts by weight: 30-50 parts of potassium feldspar, 7-15 parts of calcined kaolin, 5-10 parts of quartz, 15-25 parts of dolomite, 5-10 parts of barium carbonate, 3-8 parts of wollastonite, 8-12 parts of corundum, 3-10 parts of zinc-aluminum phosphate and 2-5 parts of strontium phosphate. The ceramic tile disclosed by the invention has a very good antiviral effect and excellent wear resistance, and is high in pollution resistance.